Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions
{{output}}
In the POLARIX trial, pola-R-CHP demonstrated improved progression-free survival (PFS) compared to R-CHOP in untreated intermediate- to high-risk DLBCL. We surveyed practicing clinicians regarding their interpretation of POLARIX, including impressions of effic... ...
